(NASDAQ: EVAX) Evaxion A's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.08%.
Evaxion A's earnings in 2026 is -$7,707,000.On average, 6 Wall Street analysts forecast EVAX's earnings for 2026 to be -$443,782,847, with the lowest EVAX earnings forecast at -$711,086,741, and the highest EVAX earnings forecast at -$8,757,226. On average, 5 Wall Street analysts forecast EVAX's earnings for 2027 to be -$323,266,738, with the lowest EVAX earnings forecast at -$613,005,811, and the highest EVAX earnings forecast at -$8,757,226.
In 2028, EVAX is forecast to generate $6,380,265 in earnings, with the lowest earnings forecast at -$8,173,411 and the highest earnings forecast at $21,893,065.